Natixis Advisors L.P. Has $3.68 Million Stake in Maximus, Inc. (NYSE:MMS)

Posted by Defense World Staff on Sep 1st, 2023

Natixis Advisors L.P. increased its holdings in Maximus, Inc. (NYSE:MMS – Free Report) by 3.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,710 shares of the health services provider’s stock after buying an additional 1,413 shares during the period. Natixis Advisors L.P. owned 0.08% of Maximus worth $3,676,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quadrant Capital Group LLC raised its position in shares of Maximus by 119.8% in the fourth quarter. Quadrant Capital Group LLC now owns 389 shares of the health services provider’s stock valued at $29,000 after buying an additional 212 shares in the last quarter. Fifth Third Bancorp raised its position in Maximus by 26.0% during the first quarter. Fifth Third Bancorp now owns 728 shares of the health services provider’s stock valued at $57,000 after purchasing an additional 150 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in Maximus during the first quarter valued at approximately $62,000. Resources Management Corp CT ADV raised its position in Maximus by 2,100.0% during the first quarter. Resources Management Corp CT ADV now owns 1,100 shares of the health services provider’s stock valued at $228,000 after purchasing an additional 1,050 shares in the last quarter. Finally, Ronald Blue Trust Inc. raised its position in Maximus by 11.0% during the first quarter. Ronald Blue Trust Inc. now owns 1,296 shares of the health services provider’s stock valued at $95,000 after purchasing an additional 128 shares in the last quarter. 99.30% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Maximus

In other news, CEO Bruce Caswell purchased 3,141 shares of the business’s stock in a transaction on Friday, August 4th. The shares were acquired at an average price of $79.07 per share, with a total value of $248,358.87. Following the completion of the transaction, the chief executive officer now owns 210,484 shares of the company’s stock, valued at approximately $16,642,969.88. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Maximus news, Director Michael J. Warren sold 2,490 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $79.53, for a total transaction of $198,029.70. Following the sale, the director now owns 3,890 shares of the company’s stock, valued at $309,371.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce Caswell purchased 3,141 shares of the business’s stock in a transaction on Friday, August 4th. The shares were purchased at an average cost of $79.07 per share, for a total transaction of $248,358.87. Following the transaction, the chief executive officer now directly owns 210,484 shares of the company’s stock, valued at approximately $16,642,969.88. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. TheStreet downgraded shares of Maximus from a “b” rating to a “c+” rating in a research report on Tuesday, August 15th. StockNews.com initiated coverage on shares of Maximus in a research note on Thursday, August 17th. They set a “hold” rating on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Maximus in a research note on Friday, August 18th. They set a “buy” rating and a $102.00 target price on the stock.

Read Our Latest Stock Report on MMS

Maximus Stock Performance

Shares of Maximus stock opened at $80.81 on Friday. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.75. Maximus, Inc. has a twelve month low of $54.46 and a twelve month high of $89.69. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of 28.86 and a beta of 0.69. The company’s fifty day moving average is $83.22 and its 200 day moving average is $81.83.

Maximus (NYSE:MMS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 2nd. The health services provider reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.14 by ($0.36). Maximus had a return on equity of 15.11% and a net margin of 3.56%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the prior year, the firm earned $0.78 EPS. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. Sell-side analysts forecast that Maximus, Inc. will post 3.88 EPS for the current year.

Maximus Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th were given a dividend of $0.28 per share. The ex-dividend date was Monday, August 14th. This represents a $1.12 dividend on an annualized basis and a yield of 1.39%. Maximus’s dividend payout ratio (DPR) is currently 40.00%.

About Maximus

(Free Report)

Maximus, Inc provides business process services (BPS) to government health and human services programs. It operates through three segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.